Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | The benefits of tebentafusp in uveal melanoma

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the future of tebentafusp, a novel immune-mobilising monoclonal TCR against cancer (ImmTAC), for patients with treatment-naïve uveal melanoma. Tebentafusp resulted superior survival in a Phase III trial (NCT03070392), and biomarkers of response such as ctDNA need to be identified in future analyses. The novel ImmTAC additionally has potential as a combination therapy with immune checkpoint inhibitors. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.